Novo Nordisk sued rival drugmaker Eli Lilly, alleging false advertising claims about relative weight-loss drug performance. (Reuters via NBC News)
GLP-1 drug use surged from 2017 to 2022, jumping 230% in adults with diabetes and 643% in those without, national data indicated. (Journal of the American Heart Association)
Meanwhile, Truveta data identified tirzepatide (Mounjaro, Zepbound) as the most popular anti-obesity and anti-diabetic medication in June 2026.
A preprint study flagged signals of frailty in seniors taking tirzepatide for weight loss. (Reuters via Yahoo!)
A Sanofi survey found that 26% of people with a first-degree relative with type 1 diabetes didn't think they were at increased risk.
